Mission

     
 

Rgenix is revolutionizing the treatment of cancer by generating first-in-class therapeutics.

 
 

Rgenix is revolutionizing the treatment of cancer by generating first-in-class therapeutics that target key nodes in cancer progression. Utilizing a discovery platform developed by Rgenix founding scientists, we have discovered several novel cancer targets that drive tumor growth and metastasis. These targets regulate key components of the tumor microenvironment, including the immune system, cancer metabolism pathways, and tumor vasculature. Rgenix is developing several first-in-class therapeutics that target these key pathways.

Our target discovery platform and scientific approach can be applied to virtually any solid tumor type, yielding novel therapeutic targets and first-in-class drugs for several high-unmet cancer types to date, including glioblastoma, lung cancer, colorectal cancer and triple-negative breast cancer, among others for which our therapies have received FDA Orphan-Drug Designation.

Our mission is to discover and develop safe, effective and commercially viable therapies that will transform the lives of cancer patients.

Science

Science underlying Rgenix’s technology and pipeline has been published in leading scientific journals.

  • Rgenix's innovation is based upon a novel target discovery platform out of Rockefeller University that has yielded several exceptional programs, including a first-in-class immuno-oncology drug that shows exciting preclinical efficacy in several high unmet need cancers.

    -Dr. Eric Rowinsky (President) -

Pipeline

Rgenix has multiple programs in preclinical development, impacting cancers diagnosed in over 500,000 Americans annually.

 
Rgenix's product pipeline addresses cancers diagnosed in more than 500,000 patients annually in the US. These cancers result in more than 250,000 deaths per year in America, with 5-year survival rates often as low as 10%-20% for patients with metastatic disease. Rgenix has exclusive worldwide rights to each of its programs below.

RGX-104

RGX-104 is an orally bioavailable small molecule LXR-agonist that Rgenix in-licensed from GlaxoSmithKline as part of a world-wide exclusive licensing agreement. RGX-104 modulates the anti-tumor immune response resulting in robust anti-tumor activity in established animal models of various cancer types, including drug-resistant tumors.  In preclinical experiments, RGX-104 has demonstrated remarkable single-agent activity as well as additivity with approved therapies, such as immune check-point inhibitors.  RGX-104 has obtained FDA Orphan Drug Designation in several solid tumor types of high-unmet need.

Various cancer types

RGX-202

RGX-202 is a small molecule that inhibits a cancer metabolism pathway involved in supplying energy to cancer cells. The target of RGX-202 is genetically amplified in several prevalent cancer types. RGX-202 has demonstrated anti-tumor activity in multiple tumor models in preclinical studies, both as a single agent as well as in combination with standard-of-care therapies.

Various cancer types

RGX-014/019

RGX-014/019 are two monoclonal antibodies that target independent components of a key pathway that drives tumor progression and metastasis of triple-negative breast cancer.

Triple negative breast cancer
 
 

Lung Cancer

 

diagnosed in US/ year

 

Colorectal Cancer

 

diagnosed in US/ year

 

Trip Neg Breast Cancer

 

diagnosed in US/ year

 

Addressable Cancers

 +

diagnosed in US/ year

Team

Rgenix’s management comprises biotech professionals with deep scientific, clinical and operational expertise.

 

Management + Board

Masoud Tavazoie, M.D., Ph.D.

Chief Executive Officer
co-founder

Masoud Tavazoie, M.D., Ph.D.

Chief Executive Officer
co-founder

Dr. Tavazoie is co-founder, Board Director, and the Chief Executive Officer of Rgenix. A physician-scientist by training, he has 15 years of experience spanning the fields of pharmacology, oncology, and small-RNA biology. He is co-inventor on multiple patents related to both small-molecule and biologic therapeutics in oncology and was instrumental in the development of the Rgenix drug discovery platform. Dr. Tavazoie received his undergraduate degree in Molecular and Cell Biology from the University of California, Berkeley, and his MD and PhD degrees from the College of Physicians & Surgeons at Columbia University. Following an internship in Internal Medicine, he completed clinical training in Dermatology at NYU, where he was later appointed as the Marion Sulzberger Research Fellow with a focus on discovery and development of novel immuno-therapeutic approaches to the treatment of melanoma and other solid tumors. He has authored publications in leading journals such as NatureCell Stem CellNature Neuroscience, and Neuron. Among his awards are the NIH Medical Scientist Training Program Fellowship, the Brunie Neural Stem Cell Award, and the Lowenfish Prize for creative research in Dermatology

Shahram Seyedin-Noor, J.D.

Chief Business Officer
co-founder

Shahram Seyedin-Noor, J.D.

Chief Business Officer
co-founder

Mr. Seyedin-Noor is co-founder, Board Director, and the Chief Business Officer of Rgenix. Prior to Rgenix, Shahram was a founding executive at NextBio, a pioneer in genomics data analysis and personalized medicine. NextBio was acquired by Illumina in 2013 (NASDAQ: ILMN). Shahram helped grow NextBio into a profitable leader in the life sciences with millions in revenues from top-tier customers such as Merck, Celgene, J&J, Regeneron, Pfizer and nearly every other major biotech/pharma company. Shahram is also an angel investor in various innovative healthcare startups, including Avantome (acq. by Illumina), Bina Technologies (acq. by Roche), Counsyl and Omada Health, among others. Earlier in his career, Shahram worked with leading tech and biotech companies as an attorney at Wilson Sonsini and Cooley, and later as an investment banker at Goldman Sachs. Shahram earned a degree in economics from Pomona College, cum laude, and obtained his JD from Harvard University, where he was Editor-in-Chief of the Harvard International Law Journal.

Linkedin: www.linkedin.com/in/shahramseyedinnoor

Eric Rowinsky, M.D.

Executive Chairman
Chair, Clinical Advisory Board

Eric Rowinsky, M.D.

Executive Chairman
Chair, Clinical Advisory Board

Eric K. Rowinsky, MD, is the Executive Chairman of Rgenix and Chair of its Clinical Advisory Board. Dr. Rowinsky is principally focused on the comprehensive development and registration strategies of cancer therapeutics of all types. Dr. Rowinsky obtained his BA degree from New York University and his MD from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996-2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC Endowed Chair for Early Drug Development from 1996-2005 and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996-2006. From 2005-2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs. From 2007-2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. Dr. Rowinsky and his team at ImClone were responsible for approvals of cetuximab (Erbitux) in various indications, as well as ramucirumab in four indications and necitumumbab in one indication. Dr. Rowinsky was the Head of Research and Development, Executive Vice President, and Chief Medical Officer at Stemline Therapeutics from 2012-2015. He is also an Adjuvant Professor of Medicine at New York University School of Medicine. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies, including a wide variety of cytotoxic and targeted anticancer therapeutics. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 310 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI. Dr. Rowinsky is on the board of directors of several public companies, including Biogen Idec Inc., Navidea Inc., Bind Therapeutics, and Fortress Biotech Inc.

Linkedin: https://www.linkedin.com/in/ericrowinsky 

David Darst, M.B.A.

Chief Operating Officer

David Darst, M.B.A.

Chief Operating Officer

Mr. Darst heads finance and drug development operations at Rgenix, and joined the company full time in April 2013.  Previously he was a venture capitalist at OrbiMed Advisors from 2007-2012.   There, he invested in leading private and public biotechnology companies developing treatments for life threatening and debilitating disorders, such as cardiovascular disease, chronic migraines, and diabetes.  He was also the founding investor in Good Start Genetics, a reproductive health company where he is still a Board Observer.  Prior to OrbiMed, Mr. Darst was a co-founder, Director, and EVP of Potentia Pharmaceuticals, which was acquired by its spin-out company, Apellis Pharmaceuticals.  Apellis is developing complement inhibitors for the treatment of age-related macular degeneration, and several other inflammatory conditions, including the rare blood disorder PNH, and COPD.   Mr. Darst is on the Board of the Alliance for Cancer Gene Therapy (ACGT), and sits on the Rockefeller University Advisory Council.  Mr. Darst received an MBA from Harvard Business School, and a BA, cum laude, from Harvard College.

Linkedin: www.linkedin.com/pub/david-darst/0/b3/114

Eduardo Martinez, Ph.D.

Vice President
Chemistry

Eduardo Martinez, Ph.D.

Vice President
Chemistry

Eduardo received his Ph.D. from the Department of Chemistry and Chemical Biology at Harvard University and his B.S. in Chemistry from the University of California, Irvine. Dr. Martinez is a medicinal chemist focused on directing drug discovery and development in high-growth biotech companies. He worked for five years at Ironwood Pharmaceuticals where he helped start the chemistry group and led a team of chemists to advance two drugs into clinical trials. In addition, Eduardo previously managed operations at Medros where he helped build a drug discovery platform utilizing fruit flies to screen for drugs. He is co-founder of Euclises Pharmaceuticals, a drug discovery company focused on commercializing coxibs for the treatment of cancer, and SARmont, a medicinal chemistry and drug design consulting firm. Eduardo has also collaborated in academic drug discovery projects at Janelia Farms Research Campus and Rockefeller University.

Foster Gonsalves, Ph.D.

Vice President
Preclinical Development

Foster Gonsalves, Ph.D.

Vice President
Preclinical Development

Foster heads preclinical development at Rgenix. Prior to Rgenix, Foster was a management consultant within the life sciences practice of Navigant Consulting/Easton Associates where he served clients in the pharmaceutical, biotech, private equity, and medical device sectors. As a consultant, Foster helped his clients address key issues in product development, valuation analysis, operations, portfolio optimization and life cycle management for both early stage and marketed products. Foster completed a Postdoctoral Fellowship at the NYU Cancer Institute where he was awarded the Kimmel Foundation Fellowship to study and develop novel modulators of the Wnt signaling pathway. Foster has authored scientific research articles and book chapters and is a named inventor on several patents. He received his Ph.D. in Molecular and Cell Biology from the University of California, Berkeley, and a B.Sc. with honors in microbiology and biochemistry from St. Xavier's College in India.

Linkedin: www.linkedin.com/pub/foster-gonsalves/4/43a/408/

Isabel Kurth, Ph.D.

Vice President
Research

Isabel Kurth, Ph.D.

Vice President
Research

Isabel received her M.Sc. in Chemistry from the University of Bern, Switzerland, and her Ph.D. from the Institute of Experimental Cancer Research (ISREC), University of Lausanne, Switzerland. Following a brief postdoctoral fellowship at Columbia University, Isabel joined The Rockefeller University to continue her research studies. As a protein biochemist, her interest has focused on various aspects of cellular proliferation in cancer, bacteria and immunology, with emphasis on DNA replication, DNA repair and telomere biology. She has authored numerous book chapters as well as international reviews and her research discoveries were published in leading journals including Nature, the EMBO journal, Journal of Experimental Medicine, and Nature Structural Molecular Biology. Isabel is a recipient of the ISREC Ph.D. fellowship and a postdoctoral fellowship from the Swiss National Research Foundation.

Linkedin: www.linkedin.com/pub/isabel-kurth/16/8a3/658

Michael Szarek, Ph.D.

Vice President
Clinical & Regulatory Affairs

Michael Szarek, Ph.D.

Vice President
Clinical & Regulatory Affairs

Michael leads clinical and regulatory affairs at Rgenix. He is also currently an advisor to Venrock and Professor and Chair of the Department of Epidemiology and Biostatistics and Associate Dean of Research Administration at SUNY Downstate Medical Center School of Public Health. Prior to Rgenix, Michael was VP of Clinical and Regulatory Affairs at Stemline where he led clinical and regulatory strategy for three oncology therapeutic products.  Michael was also Senior Director of Regulatory Affairs at ImClone, where he was responsible for regulatory strategies of development-stage treatments for cancer, and Director of Biostatistics at Pfizer, where he was the worldwide statistical lead for Lipitor (atorvastatin). Michael also serves as an academic member on clinical trial Steering Committees and Data Safety Monitoring Committees, including the Executive Steering Committee of the Odyssey Outcomes Trial of Praluent (alirocumab). He received his MS degree in biostatistics from Harvard School of Public Health and his PhD in biostatistics from New York University.

Linkedin: https://www.linkedin.com/pub/michael-szarek/10/a4/b18

Sohail Tavazoie, M.D., Ph.D.

Scientific Advisory Board
Clinical Advisory Board
co-founder

Sohail Tavazoie, M.D., Ph.D.

Scientific Advisory Board
Clinical Advisory Board
co-founder

Sohail is the Director of the Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology and Leon Hess Associate Professor at The Rockefeller University as well as senior attending medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). He received his undergraduate degree from the University of California, Berkeley, his Ph.D. from Harvard and his M.D. from Harvard Medical School (HMS) and the Harvard-MIT Division of Health Sciences and Technology. Following a residency and internship at Brigham and Women’s Hospital and HMS, he joined MSKCC as a clinical fellow and research fellow in oncology. Sohail is the recipient of the The American Society of Clinical Oncology and American Association for Cancer Research Young Investigator Award, the NIH New Innovator Award, and numerous other awards and grants.

Lab link: http://www.rockefeller.edu/research/faculty/labheads/SohailTavazoie/

Nancy Chang, Ph.D.

Scientific Advisory Board
Board Director

Nancy Chang, Ph.D.

Scientific Advisory Board
Board Director

Nancy T. Chang is an investor in and Director at Rgenix. Dr. Chang is a renowned biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation, and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug (Xolair) that focused on the allergy-related basis of asthma. In June 2003, the U.S. Food and Drug Administration approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for nearly $1 billion. Dr. Chang grew Tanox from an idea to a substantial publicly traded company pioneering innovative science. Following her success with Tanox, Dr. Chang became an angel investor in healthcare companies and performs philanthropic work in community health-education projects.

Saeed Tavazoie, Ph.D.

Chair, Scientific Advisory Board
co-founder

Saeed Tavazoie, Ph.D.

Chair, Scientific Advisory Board
co-founder

Saeed is a Professor in the Department of Biochemistry and Molecular Biophysics at Columbia University. He received his graduate training at Harvard Medical School where he developed the very first computational methods for discovering regulatory networks from large scale genomic data. He has made fundamental contributions to the field of systems biology, including methods for discovering and validating regulatory perturbations in cancer. A major focus of his laboratory is to reveal how transcription factors, microRNAs, and RNA-binding proteins orchestrate precise patterns of gene expression sub-serving pathological states. Among his many awards are the NSF CAREER and the NIH Director's Pioneer Awards.

Noam Ohana, M.A.

Board Director

Noam Ohana, M.A.

Board Director

Mr. Ohana is Managing Partner of Conegliano Ventures, LP an evergreen venture fund closely associated with one of the most prominent European industrial families.  In addition to Rgenix, Mr. Ohana has an investment in Novocure, a company that has pioneered the use of tumor treating fields (TTF) to treat GBM and other cancers. Since his investment Novocure has been granted FDA approval and recently completed an IPO. Noam Ohana is also a founding Partner of BeaconLight Capital, a global equity long-short fund where he was COO from 2010 to 2014. Prior to co-founding BeaconLight Capital, Mr. Ohana was with Atticus Capital, an institutional equity fund with $20 billion of assets under management.   Mr. Ohana represents Rgenix's Series A investors on the Board.

Scientific + Clinical Advisors

SCIENTIFIC ADVISORY BOARD

Saeed Tavazoie, Ph.D. (Chairman of SAB)

Saeed is a Professor in the Department of Biochemistry and Molecular Biophysics at Columbia University. Prior to that, he was a Professor in the Department of Molecular Biology and the Institute for Integrative Genomics at Princeton. He received his graduate training at Harvard Medical School where he developed the very first computational methods for discovering regulatory networks from large scale genomic data. He has made fundamental contributions to the field of systems biology, including methods for discovering and validating regulatory perturbations in cancer. A major focus of his laboratory is to reveal how transcription factors, microRNAs, and RNA-binding proteins orchestrate precise patterns of gene expression sub-serving pathological states. Saeed is a recipient of the NSF Career Award, the NIH Director's Pioneer Award, and numerous other scientific awards and grants.


http://systemsbiology.columbia.edu/faculty/saeed-tavazoie

Sohail Tavazoie, M.D., Ph.D.

Sohail is the Director of the Elizabeth and Vincent Meyer Laboratory of Systems Cancer Biology and Leon Hess Associate Professor at The Rockefeller University as well as senior attending medical oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC). He received his undergraduate degree from the University of California, Berkeley, his Ph.D. from Harvard University and his M.D. from Harvard Medical School (HMS) and the Harvard-MIT Division of Health Sciences & Technology. Following a residency and internship in internal medicine at Brigham and Women’s Hospital and HMS, he joined MSKCC as a clinical fellow and then as a research fellow in medical oncology. Sohail is the recipient of the The American Society of Clinical Oncology and American Association for Cancer Research Young Investigator Award, the NIH New Innovator Award, and numerous other awards and grants.


http://www.rockefeller.edu/research/faculty/labheads/SohailTavazoie/

Rich Heyman, Ph.D.

Richard A. Heyman, Ph.D., was the Chief Executive Officer and President at Seragon Pharmaceuticals Inc, which he co-founded in 2013 and sold to Genentech (Roche) in 2014. Previously, Dr. Heyman co-founded Aragon Pharmaceuticals, Inc. in 2009 and served as its Chief Executive Officer, President, and Head of Research and Development until its sale to Johnson & Johnson. He co-founded X-Ceptor Therapeutics Inc. in 1999 and served as its Chief Scientific Officer and Senior Vice President of Research through its acquisition by Exelixis in 2004. Before that, Dr. Heyman served in positions of increasing responsibility with Ligand Pharmaceuticals including Vice President of Research, where he was responsible for multiple drug discovery programs, including the successful discovery and development of Panretin (alitretinoin) and Targretin (bexarotene), retinoids approved for the treatment of cancer. Dr. Heyman has more than a dozen issued patents and has co-authored over 100 scientific publications. He was trained as an NIH postdoctoral fellow and staff scientist at the Salk Institute for Biological Studies. Dr. Heyman holds a Ph.D. in Pharmacology from University of Minnesota and a B.S. in Chemistry from University of Connecticut.

David Mangelsdorf, Ph.D.

David J. Mangelsdorf is currently the Chair of Pharmacology at UT Southwestern. He received his BS in Biology and Chemistry from Northern Arizona University in Flagstaff (1981) and his Ph.D. in Biochemistry from the University of Arizona in Tucson (1987). He did his postdoctoral studies at The Salk Institute for Biological Studies. Since 1993, he has been at UT Southwestern where he currently is Professor and Chair of the Department of Pharmacology and an Investigator of the Howard Hughes Medical Institute. He holds the Raymond and Ellen Willie Distinguished Chair in Molecular Neuropharmacology, in Honor of Harold B. Crasilneck, PhD, and he is a member of the National Academy of Sciences.

Antoni Ribas, M.D., Ph.D.

Antoni Ribas, M.D., Ph.D. is Professor of Medicine, Professor of Surgery, and Professor of Molecular and Medical Pharmacology at the University of California Los Angeles (UCLA), Director of the Tumor Immunology Program at the Jonsson Comprehensive Cancer Center (JCCC) and the Chair of the Melanoma Committee at SWOG. Trained at the University of Barcelona, with postdoctoral research and clinical fellowships at UCLA. He is a member of the American Society of Clinical Investigation (ASCI). Dr Ribas is a physician-scientist who conducts laboratory and clinical research in malignant melanoma, focusing on gene engineered adoptive cell transfer (ACT) therapies, anti-CTLA4 antibodies, anti-PD-1 antibodies, BRAF and MEK inhibitors and nanoparticle-siRNA, which have been published in major journals such as The New England Journal of Medicine, Nature, Nature Medicine and Proceedings of the National Academy of Sciences. His NIH, State of California and private foundation-supported research laboratory develops models of disease to test new therapeutic options and studies mechanism of action of treatments in patients. He has been instrumental in the clinical development of several new agents approved by the FDA, including pembrolizumab (Keytruda), vemurafenib (Zelboraf), dabrafenib (Tafinlar) and trametinib (Mekinist).

Nancy Chang, Ph.D.

Nancy T. Chang is a renowned biochemist who cofounded Tanox in 1986 to address medical needs in the areas of allergy, asthma, inflammation and diseases affecting the human immune system. Tanox took an innovative approach in developing an asthma drug (Xolair) that focused on the allergy-related basis of asthma. In June 2003, the U.S. Food and Drug Administration approved Xolair, the first biotech product cleared for treating those with asthma related to allergies. Tanox was also active in the development of TNX-355, an antibody for the treatment of HIV/AIDS. In 2007, Tanox was sold to Genentech for $919 million. Dr. Chang grew Tanox from an idea to a substantial publicly traded company pioneering innovative science. Following her success with Tanox, Dr. Chang became an angel investor in healthcare companies and performs philanthropic work in community health-education projects.

Siavash K. Kurdistani, M.D.

Siavash is Associate Professor of Biological Chemistry at the David Geffen School of Medicine at UCLA. He received his B.S. in Biochemistry from UCLA and M.D. from Harvard Medical School as an HHMI Medical Student Fellow. After residency training in Pathology and Laboratory Medicine and an HHMI postdoctoral fellowship, he joined the faculty in the UCLA Department of Biological Chemistry in 2004. His laboratory investigates how chromatin and the epigenome are integrated into the cellular metabolic network and how alterations of chromatin structure and function contribute to cancer development and progression.

Tarun Kapoor, Ph.D.

Tarun is the Pels Family Professor and Head of Laboratory of Chemistry and Cell Biology at the Rockefeller University. Dr. Kapoor earned bachelor’s degrees in chemistry and biology from the California Institute of Technology, and master’s and Ph.D. degrees in chemistry from Harvard University. During this period, Tarun developed and validated new drug discovery strategies. His post-doctoral work at the Harvard Medical School led to the first anti-mitotic agent that did not target tubulin, the only target of all clinically used anti-mitotic agents. This work catalyzed the development of new anti-cancer drugs that have entered clinical trials. His laboratory’s translational research has led to new drug candidates that target proteins whose dysfunction has been linked to cancer. His basic research program focuses on revealing molecular and physical mechanisms underlying cell division. He has served as a Consultant or Scientific Advisory Board member for several pharmaceutical and biotechnology firms developing anti-cancer drugs. His work has been recognized by many awards, including the Pew Scholar and Leukemia Lymphoma Scholar Awards.

CLINICAL ADVISORY BOARD

Eric Rowinsky, M.D. (Chairman of CAB)

Eric K. Rowinsky, MD, is principally focused on the comprehensive development and registration strategies of cancer therapeutics of all types. Dr. Rowinsky obtained his BA degree from New York University and his MD from the Vanderbilt University School of Medicine. Following his residency in internal medicine at the University of California, he completed fellowship training in medical oncology and clinical pharmacology at the Johns Hopkins University School of Medicine. From 1987 to 1996, Dr. Rowinsky served as an Associate Professor of Oncology at the Johns Hopkins University School of Medicine where he performed seminal clinical development and pharmacologic studies on paclitaxel, docetaxel, irinotecan, topotecan, among other agents. From 1996-2004, he served as the Director of Clinical Research and later Director of the Institute for Drug Development of the Cancer Therapy and Research Center in San Antonio, where he held the SBC Endowed Chair for Early Drug Development from 1996-2005 and was a lead investigator on early developmental studies of many classes of targeted therapeutics such as erlotinib, gefitinib, panitumumab, temsirolimus, ridaforolimus, trabectedin, and many other agents. He was also Clinical Professor of Medicine in the Division of Medical Oncology at the University of Texas Health Science Center at San Antonio from 1996-2006. From 2005-2007, Dr. Rowinsky served as the Chief Medical Officer and Senior Vice President at ImClone Systems, responsible for clinical development and regulatory affairs. From 2007-2009, he was an Executive Vice President of ImClone Systems, which became a wholly-owned subsidiary of Eli Lilly after its acquisition. Dr. Rowinsky and his team at ImClone were responsible for approvals of cetuximab (Erbitux) in various indications, as well as ramucirumab in four indications and necitumumbab in one indication. Dr. Rowinsky was the Head of Research and Development, Executive Vice President, and Chief Medical Officer at Stemline Therapeutics from 2012-2015. He is also an Adjuvant Professor of Medicine at New York University School of Medicine. Prior to joining ImClone in 2005, Dr. Rowinsky was a longstanding NCI principal investigator on anticancer drug development grants and integrally involved in pivotal clinical and preclinical investigations which lead to the development of both classical chemotherapeutics and targeted therapies, including a wide variety of cytotoxic and targeted anticancer therapeutics. Dr. Rowinsky is the Editor-in-Chief of Investigational New Drugs, an Associate Editor and Editorial Board Member of Cancer Research (Associate Editor and Reviews Editor), Clinical Cancer Research, Annals of Oncology, Cancer Biology and Therapy and several other oncology journals and has published approximately 310 manuscripts in both the preclinical and clinical research fields. He has also served on the Board of Directors, Scientific Advisory Board and Project Advisory Boards of a large number of pharmaceutical and biotechnology companies and has advised and/or presented aspects of New Drug Applications to the FDA on several occasions. Dr. Rowinsky’s honors include receipt of the career development award of the American Cancer Society and the 6th Annual Emil J. Freireich Award for outstanding achievement of a young researcher in clinical cancer therapeutics. He has also served on the Board of Scientific Counselors of the NCI. Dr. Rowinsky is on the board of directors of several public companies, including Biogen Idec Inc., Navidea Inc., Bind Therapeutics, and Fortress Biotech Inc.


https://www.linkedin.com/in/ericrowinsky

Richard Carvajal, M.D.

Dr. Carvajal is an oncologist/hematologist at Columbia University. He was previously a medical oncologist at the Memorial Sloan Kettering Cancer Center and an Assistant Professor at Weill Cornell Medical College. Dr. Carvajal has been a Principal Investigator for several important clinical trials of novel melanoma drugs, including cobimetinib, vemurafenib, and imatinib. He received his medical degree from the NYU School of Medicine.

Anthony Johnson, M.D.

Tony is the Head of Early Clinical Development at AstraZeneca. He serves on the Board of Cardioxyl and was previously a Venture Partner at OrbiMed Advisors. He led exploratory clinical development, biomarkers, clinical pharmacology and pharmacometrics at Bristol-Myers Squibb to superior productivity and drove translation to clinical proof of concept successfully as VP of Discovery Medicine at GlaxoSmithKline. He also established the GlaxoWelcome Medicines Research Unit and had an academic appointment at Queensland University (U.Q.) for which he achieved tenure. Tony received his medical training and research doctorate at New South Wales University and his M.P.H. from U.Q.. Tony is also a fellow of the Royal Australasian College of Physicians and is board certified in Internal Medicine, Geriatric Medicine, and Clinical Pharmacology with 18 years of broad clinical experience.

Pamela M. Klein, M.D.

Dr. Klein is a medical oncologist with strong expertise in drug development. She currently serves as an advisor/consultant on strategy and drug development to all stages of biotechnology and pharma companies. She is also an expert advisor to several Venture Capital firms. Most recently, Dr. Klein was CMO for Intellikine, where she built and led the clinical development organization enabling several first-in-man studies. Prior to that, Dr. Klein was VP of Development at Genentech where she led the development of a large portfolio of drugs, including Herceptin, that have changed the way breast cancer is treated. Prior to Genentech, Dr. Klein spent 7 years at the National Cancer Institute (NCI) where she built and developed the NCI-Navy Breast Care Center, serving as Research Director for the Center. Klein earned her medical degree from Stritch School of Medicine, Loyola University and completed her internal medicine residency training at Cedar-Sinai Hospital where she received the Leo Rigler Award for Resident of the Year, and the Ben Newman Award for the Most Humanistic Physician. She did a Medical Oncology Fellowship at the NCI, serving as Chief Fellow from 1995-996, and then went on to complete an advanced research fellowship within the Department of Genetics.

Yelena Janjigian, M.D.

Dr. Yelena Janjigian is a medical oncologist who specializes in the treatment of malignancies of the gastrointestinal tract, particularly esophagus and stomach cancers. Her research focuses on the development of new treatments for patients with esophagus and stomach cancers, and she is particularly interested in finding ways to select the best treatments for persons with cancer based on the molecular characteristics of their tumor specimens. Dr. Janjigian runs clinical and translational studies designed to develop a better understanding of the driving factors in the development of stomach and esophagus cancer to develop better prevention, early diagnosis, staging, and treatment strategies. She is the Principal Investigator of national clinical trials. Her research has been supported by grants from the National Cancer Institute and the American Society of Clinical Oncology. Dr. Janjigian earned her medical degree from the NYU School of Medicine.

Paul Chapman, M.D.

Dr. Chapman is a Medical Oncologist at Memorial Sloan-Kettering Cancer Center (MSKCC), which he joined in 1988. He is physician-scientist and specialist in melanoma metastasis, having participated in and led the early stage clinical development of several approved drugs, including vemurafenib and ipilimumab, and multiple drug therapies currently in development with novel mechanisms of action. Dr. Chapman is Vice Chairman of MSKCC’s Research Council and a Professor of Medicine at Weill Medical College of Cornell University. He was appointed to the melanoma “Dream Team” sponsored by the not-for-profit organizations Stand Up To Cancer and the Melanoma Research Alliance. Dr. Chapman received the Wings of Hope Award from the Melanoma Research Foundation in 2007. He is the author of 95 peer-reviewed publications and has been an editorial board member for the journals Cancer, Journal of Clinical Oncology, Current Cancer Therapy Reviews, and Clinical Cancer Research.

 

 

 

    • This year over 8 million people will die from cancer globally, most as a result of metastatic disease stemming from ineffective available therapies and drug resistance. We aim to save lives by developing novel drugs with robust and persistent efficacy in cancer patients who lack effective therapies.

      - Dr. Masoud Tavazoie (co-founder & CEO) -

Contact Us

     

To learn more about our science and products, please send us a message below.

 
 

Address

310 East 67th Street, Suite 1-12‎

New York, NY 10065, USA

 

Phone number

(646) 856-9261

Job Postings

Research Assistant

The Position
We have an opening for a talented Research Assistant to join our pre-clinical research group. The job responsibilities include cell culture assays, gene expression studies, characterization of various key reagents through complementary in vitro approaches in support of our drug development program. The successful candidate will be responsible for developing protein and RNA quantification assays, establishing initial assay parameters and execution of robust assay validation. This assay development will culminate in sample analysis to be run routinely internally. The position also requires testing and validating lead drug candidates and target genes in orthogonal in vivo assays, including tumor growth studies in mouse tumor models. Rgenix has close collaborations with leading NY based academic institutions, which may provide additional research opportunities.

We look for individuals who are inspired by our mission and will be highly motivated and work well within our collaborative, dynamic and team-oriented work culture.

Who You Are
The qualified individual will possess a B.S. or M.S. and at least 1 year of relevant experience. Practical experience in molecular and/or cellular assays is required. Familiarity with animal work - specifically mice - is an advantage. Strong analytical skills, critical thinking and ability to analyze quantitative data are also required. Experience or willingness to learn and implement statistical tools such as MATLAB and R for data analysis is preferred. The position requires good communication skills and the ability to work well as part of a team. It also requires excellent time management and organizational skills.

Compensation
Salary and benefits for the position are in line with biotechnology industry comps for your experience level.

Please contact Isabel Kurth, PhD, VP of Research: isabel@rgenix.com.

Senior Scientist

The Position
We are seeking a highly talented Senior Scientist with experience in cancer biology and/or immunology to join our pre-clinical research group. The successful applicant should express a keen interest in developing novel therapies and have a demonstrated record of conducting both in vitro and preferably in vivo research. The position involves the discovery, characterization, and validation of small molecule and therapeutic antibody candidates. A variety of cellular, biochemical and pharmacological methods will be employed to effectively translate innovative ideas into drugs. Job responsibilities include keeping abreast of cutting edge technology and implementing and developing new in-house methods as appropriate for both clinical and research programs. The candidate will work with and supervise Research Assistants and will function as a member of multidisciplinary project teams. He/she will present results and recommendations at local project team and related meetings.

The position will allow for growth of the selected candidate in assay development, regulatory work, and biomarker assays integral for clinical drug development.

Who You Are
The qualified individual will possess a PhD with some understanding and expertise in cancer biology, immunology, or comparable biological science with an oncology or drug development related focus. Experience with in vivo animal work is highly desired. Strong analytical skills, critical thinking and ability to analyze quantitative data are also required. Experience or willingness to learn and implement statistical tools such as MATLAB and R for data analysis is preferred. The position requires good communication skills, high self-motivation and ability to work independently in a high complexity setting. It also requires excellent team work, time management and organizational skills.

Compensation
Salary and benefits for the position are in line with biotechnology industry comps for your experience level.

Please contact Isabel Kurth, PhD, VP of Research: isabel@rgenix.com.